TrialCancer immunology, immunotherapy : CII2024

Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial.

Qin Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.